Theratechnologies (THTX) Stock Price, News & Analysis

Company Overview

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Key Stats

• Today's Range: $3.15 to $3.16
• 50-Day Range: $2.30 to $3.17
• 52-Week Range: $1.12 to $3.20
• Volume: 709,739 shs
• Average Volume: 596,911 shs
• Market Capitalization: $145.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

THTX Stock Analysis - Frequently Asked Questions

How have THTX shares performed this year?

Theratechnologies' stock was trading at $1.81 at the beginning of the year. Since then, THTX shares have increased by 74.6% and is now trading at $3.16.

How were Theratechnologies' earnings last quarter?

Theratechnologies Inc. (NASDAQ:THTX) released its quarterly earnings data on Wednesday, July, 9th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.08. The company had revenue of $17,729 billion for the quarter, compared to analyst estimates of $24.30 million.

When did Theratechnologies' stock split?

Theratechnologies shares reverse split before market open on Monday, July 31st 2023.The 1-4 reverse split was announced on Monday, July 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Does Theratechnologies have any subsidiaries?

Theratechnologies subsidiaries include these companies: Katana, Pharma-G Inc., Theratechnologies Europe Inc., Theratechnologies Europe Limited, Theratechnologies Intercontinental Inc., and Theratechnologies U.S. Inc.

Who are Theratechnologies' major shareholders?

Theratechnologies' top institutional shareholders include AIGH Capital Management LLC (4.53%) and FNY Investment Advisers LLC.

How do I buy shares of Theratechnologies?

Shares of THTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Theratechnologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Theratechnologies investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), CymaBay Therapeutics (CBAY), Novo Nordisk A/S (NVO), Adobe (ADBE) and Celestica (CLS).

Company Calendar

• Last Earnings: 7/09/2025
• Today: 8/02/2025
• Next Earnings (Estimated): 10/09/2025
• Fiscal Year End: 11/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:THTX
• CIK: 1512717
• Web: www.theratech.com
• Phone: (514) 336-7800
• Fax: 514-331-9691
• Employees: 140
• Year Founded: 1993

Profitability

• EPS (Trailing Twelve Months): ($0.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 316.00
• P/E Growth: N/A
• Net Income: -$8.31 million
• Net Margins: -10.85%
• Pretax Margin: -8.09%
• Return on Equity: N/A
• Return on Assets: -9.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.84
• Quick Ratio: 0.65

Sales & Book Value

• Annual Sales: $85.87 million
• Price / Sales: 1.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.61) per share
• Price / Book: -5.18

Miscellaneous

• Outstanding Shares: 45,980,000
• Free Float: N/A
• Market Cap: $145.30 million
• Optionable: Optionable
• Beta: 0.52